PCSK9 QUANTIFICATION BY IMMUNODETECTION
The present disclosure relates to, among other things, systems for detecting the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, lipoprotein or portions thereof and/or PCSK9 unbound lipoproteins present in a biological sample. The present invention also relates to methods of assessing the level of specific lipoprotein-bound level of PCSK9, and optionally free PCSK9, Apo B and/or PCSK9 unbound lipoproteins present in a biological sample, determining whether a subject is at increased risk for cardiovascular disease and monitoring the risk for developing cardiovascular disease.
1 . A gel electrophoresis system for detecting a level of PCSK9 bound and/or unbound to lipoprotein particles present in a biological sample comprising:
a gel substrate to receive a biological sample; and
an anti-PCSK9 antibody, at least one anti-lipoprotein antibody, or both.
2 . An immunoassay system for detecting a level of PCSK9 bound and/or unbound to lipoprotein particles present in a biological sample comprising:
an anti-lipoprotein antibody immobilized on a solid substrate; and
an anti-PCSK9 antibody, wherein the anti-PCSK9 antibody is bound to a distinct signal producing molecule capable of producing or causing production of a distinguishable detectable signal.
3 . The system of claim 1 or 2 , further comprising a non-specific protein dye.
4 . The system of claim 1 or 2 , wherein the anti-PCSK9 antibody, at least one anti-lipoprotein antibody, or both are bound to distinct signal producing molecules capable of producing or causing production of a detectable signal and wherein each detectable signal is distinguishable from the other detectable signal(s).
5 . The system of claim 1 or 2 , further comprising a device for detecting the anti-PCSK9 antibody, the at least one anti-lipoprotein antibody, a detectable signal attached thereto, a non-specific protein dye, or any combination thereof.
6 . The system of claim 1 or 2 , wherein the anti-lipoprotein antibody is selected from the group consisting of anti-lipoprotein (a), anti-apolipoprotein B (Apo B), and anti-apolipoprotein-a (apo-a).
7 . The system of claim 5 , wherein the device quantitates the level of specific lipoprotein-bound PCSK9, free PCSK9, PCSK9-free lipoprotein, PCSK9-bound lipoprotein, or any combination thereof based on said detecting.
8 . The system of claim 1 or 2 , further comprising a reagent capable of interacting with a signal producing molecule, wherein the signal producing molecule produces the detectable signal upon contact with the reagent.
9 . The system of claim 4 , wherein the detectable signal is detectable by fluorometric means.
10 . The system of claim 1 or 2 , wherein systems are non-denaturing.
11 . A method for measuring improvement or worsening of a patient undergoing treatment for hypercholesterolemia, said method comprising:
obtaining a biological sample from the patient,
measuring the amount of lipoprotein-bound PCSK9, free PCSK9, or both in the biological sample;
measuring the amount of lipoprotein-bound Apo B, free Apo B, or both in the biological sample;
optionally measuring an amount of triglyceride-rich lipoprotein (TRL) in the biological sample;
generating a ratio of bound:free PCSK9, of bound PCSK9:Apo B, and/or of bound PCSK9:TRL; and
comparing the ratio(s) generated to a reference level(s).
12 . The method of claim 11 , further comprising evaluating the level of improvement or worsening in hypercholesterolemia of the patient by a decreasing or increasing ratio.
13 . The method of claim 11 , wherein worsening of the patient undergoing treatment for hypercholesterolemia is determined when there is a greater level of PCSK9 than the reference level, the ratio of bound:free PCSK9 is greater than the reference level, the ratio of bound PCSK9:Apo B is greater than the reference level, or the ratio of bound PCSK9:TRLs is greater than the reference level.
14 . A method for assessing risk of a patient developing cardiovascular disease or progression of cardiovascular disease, said method comprising:
obtaining a biological sample from the patient,
measuring an amount of lipoprotein-bound PCSK9, free PCSK9, or both in the biological sample;
measuring an amount of lipoprotein-bound Apo B, free Apo B, or both in the biological sample;
optionally measuring an amount of triglyceride-rich lipoprotein (TRL) in the biological sample;
generating a ratio of bound:free PCSK9, of bound PCSK9:Apo B, and/or of bound PCSK9:TRL; and
comparing the ratio(s) to a reference level(s).
15 . The method of claim 14 , further comprising evaluating the level of risk of developing or progression of cardiovascular disease by a decreasing or increasing ratio.
16 . The method of claim 14 , wherein the risk of developing cardiovascular disease or progression of cardiovascular disease is determined to be higher or worsening when there is a greater level of PCSK9 than the reference level, the ratio of bound:free PCSK9 is greater than the reference level, the ratio of bound PCSK9:Apo B is greater than the reference level, or the ratio of bound PCSK9:TRLs is greater than the reference level.
17 . The method of claim 11 or 14 , wherein the lipoprotein-bound PCSK9, free PCSK9, or both is measured via an immunoassay comprising at least an anti-PCSK9 detection antibody and a signal-producing molecule physically bound to the anti-PCSK9 detection antibody and quantifying PCSK9 via signal detected from the signal-producing molecule.
18 . The method of claim 11 or 14 wherein the lipoprotein-bound Apo B, free Apo B, or both is measured via an immunoassay comprising at least an anti-Apo B detection antibody and a signal-producing molecule physically bound to the anti-Apo B detection antibody and quantifying Apo B via signal detected from the signal-producing molecule.
19 . The method of claim 11 or 14 , wherein the anti-PCSK9 antibody binds to an epitope of PCSK9 that comprises at least one residue or a plurality of residues consisting of SEQ ID NO 1, SEQ ID NO 2, SEQ ID NO 3.